Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution. * Stage I-III Hodgkin lymphoma (part 3) * Relapse or refractory disease following 1 line of multi-agent chemotherapy (not including pembro-GVD). * Eligible for HDT/ASCT * Achieved complete response (Deauville 3 or better) per clinical review following 2 cycles of pembro-GVD * Be willing and able to provide written informed consent/assent for the trial. * Be ≥ 18 years of age on day of signing informed consent. * Have measurable disease b…
Interventions
- Drugpembrolizumab
Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
- Druggemcitabine
1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
- Drugvinorelbine
20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
- Drugliposomal doxorubicin
15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
- ProcedureStem cell mobilization and collection
Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
Locations (10)
- City of Hope Cancer Center (Data Collection Only)Duarte, California
- Stanford University Medical CenterStanford, California
- University of MiamiMiami, Florida
- Memorial Sloan Kettering Basking RidgeBasking Ridge, New Jersey
- Memorial Sloan Kettering MonmouthMiddletown, New Jersey
- Memorial Sloan Kettering BergenMontvale, New Jersey